

DAFTAR PUSTAKA

- Alsadi, B., 2014. Polycystic Ovarian Syndrome: Pathophysiology and Infertility. World J. Laparosc. Surg. DVD 7, 23–27. <https://doi.org/10.5005/jp-journals-10033-1212>
- AlFadeel, M.A., AlRabeeah, N., Mirza, H., AlOtaibi, W., Alhudaib, M., AlDossary, A., AbuSharifa, N., Alwan, M., 2022. Awareness and Features of PCOS in Students of AlMaarefa. World Fam. Med. 21, 86–99.
- Al Anwar, A. M., El Sayed, M. L. M., Salim, A. M. A., & Al Salam, H. S. A. 2022. Polycystic Ovary Syndrome Phenotypes among Infertile Women in Zagazig University Hospitals. *Egyptian Journal of Hospital Medicine*, 87(1), 1436–1441. <https://doi.org/10.21608/EJHM.2022.224904>
- Arora, B., Arora, V., Patel, S., 2014. Polycystic Ovarian Syndrome: An awareness guide for women. J. Pharm. Res. Vol8 Issue 7 July 2014 884-892.
- Ashraf, S., Nabi, M., Rasool, S. ul A., Rashid, F., Amin, S., 2019. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egypt. J. Med. Hum. Genet. 20. <https://doi.org/10.1186/s43042-019-0031-4>
- Avidor, S., Abu Hamam, A., Lahav, Y., 2022. The Toll of Feeling Older: Subjective Age Moderates the Associations Between Anxiety Sensitivity and Symptoms of Anxiety and Depression During the COVID-19 Epidemic. *Journals Gerontol. - Ser. B Psychol. Sci. Soc. Sci.* 77, E5–E10.
- Azziz, R. (Ed.), 2007. The polycystic ovary syndrome: current concepts on pathogenesis and clinical care, Endocrine Updates. Springer, New York.
- Barbosa, G., de Sá, L.B.P.C., Rocha, D.R.T.W., Arbex, A.K., 2016. Polycystic Ovary Syndrome (PCOS) and Fertility. *Open J. Endocr. Metab. Dis.* 06, 58–65. <https://doi.org/10.4236/ojemd.2016.61008>
- Bahadori, F., Jahanian Sadatmahalleh, S., Montazeri, A., Nasiri, M., 2022. Sexuality and psychological well-being in different polycystic ovary syndrome phenotypes compared with healthy controls: a cross-sectional study. *BMC Womens. Health* 22, 1–12.



- Barry, J.A., 2019. Psychological Aspects of Polycystic Ovary Syndrome. Springer International Publishing, Cham. <https://doi.org/10.1007/978-3-030-30290-0>
- Barry, J.A., Kuczmierczyk, A.R., Hardiman, P.J., 2011. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. *Hum. Reprod.* 26, 2442–2451. <https://doi.org/10.1093/humrep/der197>
- Barry, J.A., Qu, F., Hardiman, P.J., 2018. An exploration of the hypothesis that testosterone is implicated in the psychological functioning of women with polycystic ovary syndrome (PCOS). *Med. Hypotheses* 110, 42–45. <https://doi.org/10.1016/j.mehy.2017.10.019>
- Benson, S., Arck, P.C., Tan, S., Hahn, S., Mann, K., Rifaie, N., Janssen, O.E., Schedlowski, M., Elsenbruch, S., 2009. Disturbed stress responses in women with polycystic ovary syndrome. *Psychoneuroendocrinology* 34, 727–735. <https://doi.org/10.1016/j.psyneuen.2008.12.001>
- Bjelland, I., Krokstad, S., Mykletun, A., Dahl, A.A., Tell, G.S., Tambs, K., 2008. Does a higher educational level protect against anxiety and depression? The HUNT study. *Soc. Sci. Med.* 66, 1334–1345.
- Carroll, J., Saxena, R., Welt, C.K., 2012. Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. *J. Pediatr. Endocrinol. Metab.* 25, 459–466.
- Chaudhry, I.B., Husain, N., Husain, M.O., Hallak, J., Drake, R., Kazmi, A., Rahman, R. ur, Hamirani, M.M., Kiran, T., Mehmood, N., Stirling, J., Dunn, G., Deakin, B., 2013. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial. *Trials* 14, 1–9.
- Cheema, H.K., Arora, R., 2019. Prevalence and Clinical Profile of Patients with Polycystic Ovary Syndrome- A Hospital Based Study. *J. Evol. Med. Dent. Sci.* 8, 2573–2576.
- Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H.F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, ., Pfeifer, M., Pignatelli, D., Pugeat, M., Yildiz, B.O., 2014. The polycystic ovary syndrome: a position statement from the European society of Endocrinology. *Eur. J. Endocrinol.* 171, P1–P29. <https://doi.org/10.1530/EJE-14-0253>



- Crespo, R.P., Bachega, T.A.S.S., Mendonça, B.B., Gomes, L.G., 2018. An update of genetic basis of PCOS pathogenesis. *Arch. Endocrinol. Metab.* 62, 352–361. <https://doi.org/10.20945/2359-39970000000049>
- Dybciak, P., Humeniuk, E., Racziewicz, D., Krakowiak, J., Wdowiak, A., Bojar, I., 2022. Anxiety and Depression in Women with Polycystic Ovary Syndrome. *Med.* 58.
- Dziurkowska, E., Wesolowski, M., 2021. Cortisol as a biomarker of mental disorder severity. *J. Clin. Med.* 10.
- Ehrmann, D.A., 2005. Polycystic Ovary Syndrome. *N. Engl. J. Med.* 352, 1223–1236. <https://doi.org/10.1056/NEJMra041536>
- Elasam, A.N., Ahmed, M.A., Ahmed, A.B.A., Sharif, M.E., Abusham, A., Hassan, B., Adam, I., 2022. The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. *BMC Womens. Health* 22, 1–7.
- Falcetta, P., Benelli, E., Molinaro, A., Di Cosmo, C., Bagattini, B., Del Ghianda, S., Salvetti, G., Fiore, E., Pucci, E., Fruzzetti, F., Tonacchera, M., 2021. Effect of aging on clinical features and metabolic complications of women with polycystic ovary syndrome. *J. Endocrinol. Invest.* 44, 2725–2733.
- Farkas, J., Rigó, A., Demetrovics, Z., 2013. Psychological aspects of the polycystic ovary syndrome. *Gynecol. Endocrinol.* 30, 95–99. <https://doi.org/10.3109/09513590.2013.852530>
- Fatemeh, B., Shahideh, J.S., Negin, M., 2021. Health related quality of life and psychological parameters in different polycystic ovary syndrome phenotypes: a comparative cross-sectional study. *J. Ovarian Res.* 14, 1–19.
- Fornes, R., 2017. Polycystic ovary syndrome (PCOS): role of androgens and obesity on placental function and fetal development.
- Głowińska, A., Zielona-Jenek, M., Pawelczyk, A., Banaszewska, B.E., 2016. Determinants of emotional problems and mood disorders in women with polycystic ovary syndrome. *Ginekol. Pol.* 87, 405–410. <https://doi.org/10.5603/GP.2016.0016>
- O., Stopińska-Głuszak, U., Glinicki, P., Kapuścińska, R., Snochowska, ., Zgliczyński, W., Dębski, R., 2012. Phenotype and metabolic disorders



- in polycystic ovary syndrome. *ISRN Endocrinol.* 2012, 569862.
<https://doi.org/10.5402/2012/569862>
- Gnocchi, D., Bruscalupi, G., 2017. Circadian Rhythms and Hormonal Homeostasis: Pathophysiological Implications. *Biology* 6, 10.
<https://doi.org/10.3390/biology6010010>
- Hamilton, 1959. Hamilton Anxiety Rating Scale (HAM-A). *Br J Med Psychol* 1959 3250–55.
- Hasan, M., Sultana, S., Sohan, M., Parvin, S., Ashrafur Rahman, M., Jamal Hossain, M., Rahman, M.S., Rabiul Islam, M., 2022. Prevalence and associated risk factors for mental health problems among patients with polycystic ovary syndrome in Bangladesh: A nationwide cross-sectional study. *PLoS One* 17, 1–16.
- Hestiantoro, A., 2016. Konsensus tatalaksana sindrom ovarium polikistik. Himpunan Endokrinologi Reproduksi dan Fertilitas Indonesia (HIFERI) Perkumpulan Obstetri dan Ginekologi Indonesia (POGI).
- Hinds, J.A., Sanchez, E.R., 2022. The Role of the Hypothalamus–Pituitary–Adrenal (HPA) Axis in Test-Induced Anxiety: Assessments, Physiological Responses, and Molecular Details. *Stresses* 2, 146–155.
- Joseph, D., Whirledge, S., 2017. Stress and the HPA Axis: Balancing Homeostasis and Fertility. *Int. J. Mol. Sci.* 18, 2224.
<https://doi.org/10.3390/ijms18102224>
- Jorm, A.F., 2000. Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. *Psychol. Med.*
- Kabel, M.A., 2016. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and non- pharmacological treatment. 1Department Pharmacol. Fac. Med. Tanta Univ. Tanta Egypt.
- Karadağ, A.S., You, Y., Danarti, R., Al-Khuzaei, S., Chen, W., 2018. Acanthosis nigricans and the metabolic syndrome. *Clin. Dermatol.* 36, 48–53.
<https://doi.org/10.1016/j.clindermatol.2017.09.008>
- Y., Uemura, T., Ishikawa, M., Yokoi, N., Hirahara, F., 1999. Classification of polycystic ovary syndrome into three types according to response to human corticotropin-releasing hormone. *Dep. Obstet. gynecol. Yokohama City Univ. Sch. Med. Yokohama Jpn.*



- Krishnan, A., Muthusami, S., 2017. Hormonal alterations in PCOS and its influence on bone metabolism. *J. Endocrinol.* 232, R99–R113. <https://doi.org/10.1530/JOE-16-0405>
- Kshetrimayum, C., Sharma, A., Mishra, V.V., Kumar, S., 2019. Polycystic ovarian syndrome: Environmental/ occupational, lifestyle factors; an overview. *J. Turkish Ger. Gynecol. Assoc.* 20, 255–263.
- Kurniawati, E.Y., Hadisaputro, S., School of Health Sciences, Ministry of Health Semarang, Suwandono, A., Universitas Diponegoro, Semarang, Central Java, 2019. The Effect of Holistic Programs on Cortisol Serum Levels in Polycystic Ovarium Syndrome. *Indones. J. Med.* 4, 376–382. <https://doi.org/10.26911/theijmed.2019.04.04.11>
- Lee, T.T., Rausch, M.E., 2012. Polycystic Ovarian Syndrome: Role of Imaging in Diagnosis. *RadioGraphics* 32, 1643–1657. <https://doi.org/10.1148/rg.326125503>
- Lim, A. J. R., Indran, I. R., Kramer, M. S., & Yong, E. 2019. Phenotypic spectrum of polycystic ovary syndrome and their relationship to the circadian biomarkers, melatonin and cortisol. *Endocrinology, Diabetes & Metabolism*, 2(3), 1–9. <https://doi.org/10.1002/edm2.47>.
- Lin, H., Liu, M., Zhong, D., Ng, E.H.Y., Liu, J., Li, J., Shi, Y., Zhang, C., Wen, X., Mai, Z., Ou, M., Ma, H., 2021. The Prevalence and Factors Associated With Anxiety-Like and Depression-Like Behaviors in Women With Polycystic Ovary Syndrome. *Front. Psychiatry* 12, 1–12.
- Lucidi, R., 2019. What is the modified Ferriman-Gallwey (mFG) scoring system and how is it used in the evaluation of suspected polycystic ovarian syndrome (PCOS)? Medscape.
- McCartney, C.R., Marshall, J.C., 2016. Polycystic Ovary Syndrome. *N. Engl. J. Med.* 375, 54–64. <https://doi.org/10.1056/NEJMcp1514916>
- Meek, C.L., Bravis, V., Don, A., Kaplan, F., 2013. Polycystic ovary syndrome and the differential diagnosis of hyperandrogenism. *Obstet. Gynaecol.* 15, 171–176. <https://doi.org/10.1111/tog.12030>
- Sharma, S., Azziz, R., Seeman, T., Calderon-Margalit, R., Daviglus, M., Kiefe, D., Matthews, K., Sternfeld, B., Siscovick, D., 2011. Socioeconomic status and polycystic ovary syndrome. *J. Women's Heal.* 20, 413–419.



- Moran, L.J., Deeks, A.A., Gibson-Helm, M.E., Teede, H.J., 2012. Psychological parameters in the reproductive phenotypes of polycystic ovary syndrome. *Hum. Reprod.* 27, 2082–2088.
- Muharam, R., Purba, J.S., Hestiantoro, A., Elvira, S.D., 2018. Profile on personality types and cortisol in polycystic ovarian syndrome. *Middle East Fertil. Soc. J.* 23, 189–194. <https://doi.org/10.1016/j.mefs.2017.12.001>
- Mura, G., Cossu, G., Migliaccio, G.M., Atzori, C., Nardi, A.E., Machado, S., Carta, M.G., 2014. Quality of Life, Cortisol Blood Levels and Exercise in Older Adults: Results of a Randomized Controlled Trial. *Clin. Pract. Epidemiol. Ment. Heal.* 10, 67–72.
- Naz, M.S.G., Tehrani, F.R., Lak, T.B., Mohammadzadeh, F., Nasiri, M., Badr, F.K., Ozgoli, G., 2020. Quality of life and emotional states of depression, anxiety and stress in adolescents with polycystic ovary syndrome: A cross-sectional study. *Psychol. Res. Behav. Manag.* 13, 203–209.
- Ndefo, U.A., Eaton, A., Green, M.R., 2013. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. *P T* 38, 336–355.
- O'Reilly, M.W., Taylor, A.E., Crabtree, N.J., Hughes, B.A., Capper, F., Crowley, R.K., Stewart, P.M., Tomlinson, J.W., Arlt, W., 2014. Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. *J. Clin. Endocrinol. Metab.* 99, 1027–1036. <https://doi.org/10.1210/jc.2013-3399>.
- Pagana, K., Pagana, T.J., Pagana, T.N., 2018. *Mosby's manual of Diagnostic and Laboratory Test*. Elsevier, India.
- Park, S.H., Park, I.H., Lim, S.T., Lee, E., 2020. Changes in psychological anxiety and physiological stress hormones in korea national shooters. *Brain Sci.* 10, 1–9.
- Ribeiro, O., Teixeira, L., Araújo, L., Rodríguez-Blázquez, C., Calderón-Larrañaga, A., Forjaz, M.J., 2020. Anxiety, depression and quality of life in older adults: Trajectories of influence across age. *International Journal of Environmental Research and Public Health* [revista en Internet] 2020 cceso 10 de mayo de 2021]; 17(23): 1–10. *Int. J. Environment Res. Public Heal.* 17, 1–10.



- Rosa Maciel, G.A., 2013. Polycystic Ovary Syndrome: Correlation between Phenotypes and Metabolic Syndrome. *J. Steroids Horm. Sci.* 05. <https://doi.org/10.4172/2157-7536.1000132>
- Sachdeva, G., Gainder, S., Suri, V., Sachdeva, N., Chopra, S., 2019. Comparison of the different PCOS phenotypes based on clinical metabolic, and hormonal profile, and their response to clomiphene. *Indian J. Endocrinol. Metab.* 23, 326–331.
- Savas, K., Burcu, H., Gökhan, K., 2022. Phenotypes of polycystic ovary syndrome and accompanying hormonal disturbances. *Sanamed* 17, 8–8.
- Shariat, M., Haghollahi, F., Bagheri, M., 2018. The Association of Serum Hepcidin Levels and Insulin Resistance in PCOS Patients: A Case-Control Study 210–16.
- Soysal, C., Biyik, I., Ince, O., Erten, O., 2022. Comparison of the different PCOS phenotypes based on monocyte to HDL cholesterol ratio. *J. Obs. Gynecol.*
- Steegers-Theunissen, R., Wiegel, R., Jansen, P., Laven, J., Sinclair, K., 2020. Polycystic Ovary Syndrome: A Brain Disorder Characterized by Eating Problems Originating during Puberty and Adolescence. <https://doi.org/Int. J. Mol. Sci. 2020, 21, 8211; doi:10.3390/ijms21218211>
- Tabassum, F., Jyoti, C., Sinha, H.H., Dhar, K., Akhtar, M.S., 2021. Impact of polycystic ovary syndrome on quality of life of women in correlation to age, basal metabolic index, education and marriage. *PLoS One* 16, 1–13.
- Takahashi, T., Ikeda, K., Ishikawa, M., Kitamura, N., Tsukasaki, T., Nakama, D., Kameda, T., 2005. Anxiety, reactivity, and social stress-induced cortisol elevation in humans. *Neuro Endocrinol. Lett* 26, 351–354.
- Tock, L., Carneiro, G., Pereira, A.Z., Tufik, S., Zanella, M.T., 2014. Adrenocortical Production Is Associated with Higher Levels of Luteinizing Hormone in Nonobese Women with Polycystic Ovary Syndrome. *Int. J. Endocrinol.* 2014. <https://doi.org/10.1155/2014/620605>
- Tomas, C., Newton, J., Watson, S., 2013. A Review of Hypothalamic-Pituitary-adrenal Axis Function in Chronic Fatigue Syndrome. *ISRN Neurosci.* 2013, 1–8. <https://doi.org/10.1155/2013/784520>
- zidou, T., Honour, J.W., Conway, G.S., 2003. Altered Cortisol metabolism in Polycystic Ovary Syndrome: Insulin Enhances 5 α -



- Reduction But Not the Elevated Adrenal Steroid Production Rates. *J. Clin. Endocrinol. Metab.* 88, 5907–5913. <https://doi.org/10.1210/jc.2003-030240>
- Wahyuni, A., Supriyatiningsih, Kusumawati, W., Kirana, K., Mayayustika, C., 2022. Family History of PCOS, Obesity, Low Fiber Diet, and Low Physical Activity Increase The Risk of PCOS. *Indones. J. Med. Heal.* 13, 50–56.
- Wang, L., Lv, S., Li, F., Yu, X., Bai, E., Yang, X., 2020. Vitamin D Deficiency Is Associated With Metabolic Risk Factors in Women With Polycystic Ovary Syndrome: A Cross-Sectional Study in Shaanxi China. *Front. Endocrinol. (Lausanne)*. 11, 1–7.
- Welt, C.K., Carmina, E., 2013. Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause. *J. Clin. Endocrinology Metab.* 98.
- Yesiladali, M., Yazici, M. G. K., Attar, E., & Kelestimur, F. 2022. Differentiating Polycystic Ovary Syndrome from Adrenal Disorders. *Diagnostics*, 12(9), 1–14. <https://doi.org/10.3390/diagnostics12092045>.
- Zhang, J., Bao, Y., Zhou, X., Zheng, L., 2019. Polycystic ovary syndrome and mitochondrial dysfunction. *Reprod. Biol. Endocrinol.* 17. <https://doi.org/10.1186/s12958-019-0509-4>



L

A

M

P

I

R

A

N



Lampiran 1

NASKAH PENJELASAN UNTUK RESPONDEN

Selamat pagi/siang/sore, Ibu. Saya, dr. Ummi Shulaeha, yang akan melakukan penelitian tentang ***“HUBUNGAN ANTARA FENOTIPE DAN KORTISOL DENGAN STATUS KECEMASAN SINDROM OVARIUM POLIKISTIK ”***

Insiden SOPK terus mengalami peningkatan dan mengakibatkan dampak buruk, seperti siklus menstruasi (haid) yang tidak teratur, pertumbuhan rambut tubuh menyerupai pria, menurunnya kesuburan pasien, dan berujung pada sulit memperoleh keturunan. Hal-hal inilah yang menyebabkan kadar kortisol pasien SOPK meningkat dan mempengaruhi tingkat kecemasan pasien SOPK.

Karena itu kami sangat mengharapkan ibu bersedia untuk ikut dalam penelitian ini secara sukarela dan mengizinkan kami menggunakan data ibu dalam laporan tertulis maupun laporan secara lisan. Bila ibu bersedia kami mengharapkan ibu memberikan persetujuan secara tertulis. Keikutsertaan ibu dalam penelitian ini bersifat sukarela tanpa paksaan, oleh karena itu ibu berhak untuk menolak atau mengundurkan diri tanpa risiko kehilangan hak untuk mendapatkan pelayanan kesehatan di rumah sakit ini.

Kalau ibu setuju untuk berpartisipasi, kami akan menanyakan a hal antara lain data pribadi ibu dan riwayat menstruasi, ian obat serta riwayat keluarga. Kami juga akan melakukan



pengambilan sampel darah sebanyak 3 cc (kurang lebih 1 sendok makan) melalui pembuluh darah lengan, untuk pemeriksaan kortisol serum sewaktu, yang akan diperiksa di Laboratorium Prodia.

Kami menjamin keamanan dan kerahasiaan semua data pada penelitian ini. Data akan disimpan dengan baik dan aman, sehingga hanya bisa dilihat oleh yang berkepentingan saja. Demikian juga pada penyajian baik tertulis maupun pada laporan lisan, data pribadi ibu tetap akan kami rahasiakan. Data penelitian ini akan disajikan pada:

- Program Pendidikan Dokter Spesialis Obstetri dan Ginekologi Fakultas Kedokteran Universitas Hasanuddin (FK UNHAS) Makassar
- Publikasi pada majalah ilmiah dalam dan luar negeri

Bila ibu merasa masih ada hal yang belum jelas atau belum dimengerti dengan baik, maka ibu dapat menanyakan atau minta penjelasan pada saya: dr. Ummi Shulaeha (082219995028).

Jika ibu setuju untuk berpartisipasi, diharapkan menandatangani surat persetujuan mengikuti penelitian. Atas kesediaan dan kerja samanya kami ucapkan banyak terima kasih.

Identitas Peneliti

Nama : dr. Ummi Shulaeha

Alamat : PPDS Obstetri dan Ginekologi FK UNHAS Makassar

Telepon : 082219995028



Lampiran 2

FORMULIR PERSETUJUAN MENGIKUTI PENELITIAN SETELAH SUBJEK PENELITIAN MENDAPAT PENJELASAN

Yang bertanda tangan di bawah ini:

Nama :

Umur :

Alamat :

dengan ini menyatakan bahwa saya telah mendapatkan penjelasan dan memahami sepenuhnya maksud dan tujuan penelitian ini.

Saya menyatakan setuju untuk ikut serta dalam penelitian ini. Untuk itu, saya bersedia dan tidak keberatan memenuhi semua ketentuan yang berlaku dalam penelitian ini dan memberikan keterangan yang sebenarnya. Saya tahu bahwa keikutsertaan saya ini bersifat sukarela tanpa paksaan, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini tanpa kehilangan hak saya untuk mendapat pelayanan kesehatan. Saya juga berhak bertanya atau meminta penjelasan pada peneliti bila masih ada hal yang belum jelas atau masih ada hal yang ingin saya ketahui tentang penelitian ini.

Saya juga mengerti bahwa semua biaya yang dikeluarkan sehubungan dengan penelitian ini, akan ditanggung oleh peneliti. Demikian juga biaya perawatan dan pengobatan bila terjadi hal-hal yang tidak

an akibat penelitian ini, akan dibiayai oleh peneliti.



Demikianlah pernyataan ini saya buat dengan penuh kesadaran untuk dapat dipergunakan sebagaimana mestinya.

	NAMA	TANDA TANGAN	Tanggal
Saksi	xxxxxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxx
1			
Saksi	xxxxxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxx
2			

Penanggung Jawab Penelitian

Nama : dr. Ummi Shulaeha
 Alamat : Villa Mangga 3/A9 no. 16, Pacerakkang, Makassar
 Telepon : 082219995028

Penanggung Jawab Medis

Nama : Dr. dr. Hj. Andi Mardiah Tahir, Sp. OG (K)
 Alamat : Jln. Sunu G/5, Makassar
 Telepon : 082192283146



Lampiran 3

FORMULIR PENELITIAN

**HUBUNGAN ANTARA FENOTIPE DAN KORTISOL DENGAN STATUS
KECEMASAN SINDROM OVARIUM POLIKISTIK**

I. IDENTITAS PASIEN

1. Nama :
2. Rumah Sakit/ No. Reg :
3. Tanggal MRS :
4. Pekerjaan :
5. Pendidikan terakhir :
6. Pekerjaan suami :
7. Alamat :
8. Suku bangsa :
9. No. HP/ telepon :

II. DATA UMUM PASIEN

1. Umur :
2. Umur pertama menikah :
3. Lama perkawinan :
4. Menarche :
- Siklus menstruasi :
- Hirsutisme :
- Riwayat keguguran :



8. Penggunaan KB hormonal :
9. Riwayat DM :
10. Riwayat hipotiroid :
11. Berat badan (kg) :
12. Tinggi badan (cm) :
13. IMT (kg/m^2) :
14. Kenaikan BB (kg) :
15. Tekanan darah (mmHg) :
16. Hasil USG :

III. DATA KLINIS PASIEN

1. Keadaan umum : baik / sakit ringan / lemah
2. Keluhan :
3. Riwayat penyakit :
4. Riwayat operasi :
5. Riwayat penyakit keluarga :
6. Riwayat merokok :

Kortisol serum sewaktu :

HAM-A Scale :



Lampiran 4

SKALA UKUR ANSIETAS HAMILTON (Hamilton Rating Scale for Anxiety)

Nama :

Umur :

Alamat :

Pendidikan :

Pekerjaan :

Tanggal Pemeriksaan :

Keterangan nilai skor

- 0 = Tidak ada gejala
 1 = Satu dari gejala yang ada
 2 = Separuh dari gejala yang ada
 3 = Lebih dari separuh gejala yang ada
 4 = Semua gejala ada

Gejala Kecemasan		Nilai (Skor)				
1.	Perasaan cemas (ansietas) 1) Cemas 2) Firasat buruk 3) Takut akan perasaan sendiri 4) Mudah tersinggung	0	1	2	3	4
2.	Ketegangan 1) Merasa tegang 2) Lesu 3) Tidak bisa istirahat tenang 4) Mudah terkejut 5) Mudah menangis 6) Gemetar 7) Gelisah	0	1	2	3	4
3.	Ketakutan 1) Pada gelap 2) Pada orang asing 3) Ditinggal sendiri 4) Pada binatang besar 5) Pada keramaian lalu lintas 6) Pada kerumunan orang banyak	0	1	2	3	4
4.	Gangguan tidur 1) Sukar masuk tidur 2) Terbangun malam hari 3) Tidur tidak nyenyak 4) Bangun dengan lesu 5) Banyak mimpi-mimpi 6) Mimpi buruk 7) Mimpi menakutkan	0	1	2	3	4



5.	Gangguan kecerdasan 1) Sulit konsentrasi 2) Daya ingat menurun 3) Daya ingat buruk	0	1	2	3	4
6.	Perasaan depresi 1) Hilangnya minat 2) Berkurangnya kesenangan pada hobi 3) Sedih 4) Bangun dini hari 5) Perasaan berubah-ubah sepanjang hari	0	1	2	3	4
7.	Gejala somatik/fisik (otot) 1) Sakit dan nyeri-nyeri otot 2) Kaku 3) Kedutan otot 4) Gigi gemeretak 5) Suara tidak stabil	0	1	2	3	4
8.	Gejala somatik/fisik (sensorik) 1) Tinnitus (telinga mendengung) 2) Penglihatan kabur 3) Muka merah atau pucat 4) Merasa lemas 5) Perasaan ditusuk-tusuk	0	1	2	3	4
9.	Gejala kardiovaskular 1) Denyut jantung cepat 2) Berdebar-debar 3) Nyeri di dada 4) Denyut nadi mengeras 5) Lemas seperti mau pingsan 6) Denyut jantung menghilang (berhenti sekejap)	0	1	2	3	4
10.	Gejala respiratori 1) Rasa tertekan/sempit dada 2) Rasa tercekik 3) Sering menarik napas 4) Napas pendek/sesak	0	1	2	3	4
11.	Gejala gastrointestinal 1) Sulit menelan 2) Perut melilit 3) Gangguan pencernaan 4) Nyeri sebelum/sesudah makan 5) Perasaan terbakar di perut 6) Rasa penuh atau kembung 7) Mual 8) Muntah 9) Buang air besar lembek 10) Sulit buang air besar 11) Kehilangan berat badan	0	1	2	3	4
12.	Gejala urogenital 1) Sulit buang air kecil 2) Tidak dapat menahan air seni 3) Tidak datang bulan 4) Darah haid berlebihan 5) Darah haid amat sedikit 6) Masa haid berkepanjangan	0	1	2	3	4



	7) Masa haid amat pendek 8) Haid beberapa kali dalam sebulan 9) Menjadi dingin 10) Ejakulasi dini 11) Ereksi lemah 12) Impotensi					
13.	Gejala otonom 1) Mulut kering 2) Muka merah 3) Mudah berkeringat 4) Kepala pusing 5) Kepala terasa berat 6) Kepala terasa sakit 7) Bulu-bulu berdiri	0	1	2	3	4
14.	Tingkah laku saat wawancara 1) Gelisah 2) Tidak tenang 3) Jari gemetar 4) Kening berkerut 5) Muka tegang 6) Otot tegang/mengeras 7) Napas pendek dan cepat 8) Muka merah	0	1	2	3	4

Interpretasi:

- < 14 : tidak ada kecemasan
- 14 – 20 : kecemasan ringan
- 21 – 27 : kecemasan sedang
- 28 – 41 : kecemasan berat
- 42 – 56 : kecemasan sangat berat

Skor:



Lampiran 5. Tabel Induk

N o	Peke rjaan	Pend idika n	U m ur	IMT	Riw Kel PCOS	Men arch e	Nilai Kortisol	Skor kecema san	INTER PRETA SI	Fenoti pe PCO
1	Resid en	S1	32	Overw eigh	Tidak ada	13	8.4874	17	RINGA N	A
2	IRT	S1	28	Overw eigh	Tidak ada	15	10.4270	21	SEDA NG	D
3	Bidan	D3	28	Overw eigh	Tidak ada	13	6.2945	20	RINGA N	D
4	Bidan	D3	33	Obes	Tidak ada	11	13.1584	18	RINGA N	C
5	Bidan	D3	38	Obes	Tidak ada	12	11.2469	22	SEDA NG	C
6	Wiras wasta	SMK	23	Obes	Ada	11	4.2650	16	RINGA N	A
7	Bidan	D3	27	Overw eigh	Tidak ada	14	5.4883	15	RINGA N	A
8	Swas ta	S1	26	Obes	Tidak ada	14	4.3707	14	RINGA N	C
9	Swas ta	D4	29	Overw eigh	Tidak ada	11	7.6293	21	SEDA NG	A
10	Bidan	D3	24	Obes	Tidak ada	13	4.6330	21	SEDA NG	C
11	IRT	S1	23	Overw eigh	Tidak ada	14	6.4738	14	RINGA N	D
12	IRT	SMA	28	Obes	Tidak ada	14	5.0989	16	RINGA N	C
13	Swas ta	SMA	36	Overw eigh	Tidak ada	15	3.7300	14	RINGA N	C
14	IRT	S1	24	Obes	Tidak ada	14	4.5826	14	RINGA N	D
15	IRT	SMA	26	Obes	Tidak ada	15	2.6910	15	RINGA N	C
16	IRT	SMA	29	Overw eigh	Tidak ada	15	5.6776	21	SEDA NG	D
17	IRT	SMA	23	Obes	Tidak ada	15	2.3812	21	SEDA NG	D
18	Dokte r gigi	S2	24	Overw eigh	Tidak ada	13	8.7541	21	SEDA NG	A
19	IRT	S2	28	Obes	Tidak ada	12	5.2595	21	SEDA NG	C
20	Dokte r Muda	S1	22	Norma l	Ada	12	7.4980	21	SEDA NG	A
21	Resid en	S1	27	Obes	Ada	15	11.4163	21	SEDA NG	A
		S1	35	Overw eigh	Tidak ada	13	3.0471	21	SEDA NG	C
		D3	33	Overw eigh	Tidak ada	12	10.8976	21	SEDA NG	C
		S1	26	Overw eigh	Tidak ada	15	6.7278	14	RINGA N	A



25	IRT	S1	28	Normal	Tidak ada	13	10.3124	21	SEDANG	A
26	Wiraswasta	SMK	30	Normal	Tidak ada	13	4.0358	15	RINGAN	C
27	Swasta	S1	29	Obes	Tidak ada	15	6.1885	17	RINGAN	D
28	Swasta	S1	25	Obes	Tidak ada	13	4.4001	21	SEDANG	D
29	swasta	S1	33	Obes	Tidak ada	12	6.4941	14	RINGAN	C
30	Bidan	D3	34	Obes	Tidak ada	12	8.2325	15	RINGAN	C
31	wiraswasta	S1	32	Obes	Tidak ada	15	8.1848	18	RINGAN	C
32	Residen	S1	32	Obes	Tidak ada	15	6.5283	17	RINGAN	D
33	Bidan	D3	32	Overweigh	Tidak ada	15	10.9926	17	RINGAN	A
34	Bidan	D3	31	Obes	Tidak ada	15	13.1391	21	SEDANG	D
35	Bidan	D3	25	Normal	Tidak ada	15	4.0113	21	SEDANG	D
36	Dokter	S1	26	Obes	Tidak ada	16	7.2929	20	RINGAN	C
37	Peraawat	D3	32	Overweigh	Tidak ada	13	10.7183	14	RINGAN	A
38	Swasta	sma	40	Overweigh	Tidak ada	15	5.0082	17	RINGAN	C
39	Peraawat	D3	24	Overweigh	Tidak ada	14	9.2342	18	RINGAN	C
40	IRT	SMA	24	Overweigh	Tidak ada	15	10.1082	17	SEDANG	C



Lampiran 6. Hasil Olah Data

Anxiety					
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	RINGAN	23	57.5	57.5	57.5
	SEDANG	17	42.5	42.5	100.0
	Total	40	100.0	100.0	

Riwayat_PCOS * Fenotipe

Crosstab						
		Fenotipe			Total	
		A	C	D		
Riwayat_PCOS	Ada	Count	3	0	0	3
		% within Riwayat_PCOS	100.0%	0.0%	0.0%	100.0%
		% within Fenotipe	27.3%	0.0%	0.0%	7.5%
		% of Total	7.5%	0.0%	0.0%	7.5%
	Tidak ada	Count	8	18	11	37
		% within Riwayat_PCOS	21.6%	48.6%	29.7%	100.0%
		% within Fenotipe	72.7%	100.0%	100.0%	92.5%
		% of Total	20.0%	45.0%	27.5%	92.5%
Total		Count	11	18	11	40
		% within Riwayat_PCOS	27.5%	45.0%	27.5%	100.0%
		% within Fenotipe	100.0%	100.0%	100.0%	100.0%
		% of Total	27.5%	45.0%	27.5%	100.0%



Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	8.550 ^a	2	.014
Likelihood Ratio	8.420	2	.015
N of Valid Cases	40		

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is ,83.

Anxiety * Fenotipe

Crosstab

			Fenotipe			Total
			A	C	D	
Anxiety	RINGAN	Count	6	12	5	23
		% within Anxiety	26.1%	52.2%	21.7%	100.0%
		% within Fenotipe	54.5%	66.7%	45.5%	57.5%
		% of Total	15.0%	30.0%	12.5%	57.5%
	SEDANG	Count	5	6	6	17
		% within Anxiety	29.4%	35.3%	35.3%	100.0%
		% within Fenotipe	45.5%	33.3%	54.5%	42.5%
		% of Total	12.5%	15.0%	15.0%	42.5%
Total		Count	11	18	11	40
		% within Anxiety	27.5%	45.0%	27.5%	100.0%
		% within Fenotipe	100.0%	100.0%	100.0%	100.0%
		% of Total	27.5%	45.0%	27.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Chi-Square	1.311 ^a	2	.519
Ratio	1.317	2	.518
Cases	40		



a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 4,68.

Umur_kategori * Fenotipe

		Crosstab			
		Fenotipe			Total
		A	C	D	
Umur_kategori < 30 tahun	Count	8	8	9	25
	% within Umur_kategori	32.0%	32.0%	36.0%	100.0%
	% within Fenotipe	72.7%	44.4%	81.8%	62.5%
	% of Total	20.0%	20.0%	22.5%	62.5%
> = 30 tahun	Count	3	10	2	15
	% within Umur_kategori	20.0%	66.7%	13.3%	100.0%
	% within Fenotipe	27.3%	55.6%	18.2%	37.5%
	% of Total	7.5%	25.0%	5.0%	37.5%
Total	Count	11	18	11	40
	% within Umur_kategori	27.5%	45.0%	27.5%	100.0%
	% within Fenotipe	100.0%	100.0%	100.0%	100.0%
	% of Total	27.5%	45.0%	27.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	4.746 ^a	2	.093
Likelihood Ratio	4.872	2	.087
N of Valid Cases	40		

33,3%) have expected count less than 5. The minimum count is 4,13.



IMT_kategori * Fenotipe

Crosstab

			Fenotipe			Total
			A	C	D	
IMT_kategori	Obesitas	Count	3	10	6	19
		% within	15.8%	52.6%	31.6%	100.0%
		IMT_kategori				
		% within Fenotipe	27.3%	55.6%	54.5%	47.5%
		% of Total	7.5%	25.0%	15.0%	47.5%
	Non-obesitas	Count	8	8	5	21
		% within	38.1%	38.1%	23.8%	100.0%
		IMT_kategori				
		% within Fenotipe	72.7%	44.4%	45.5%	52.5%
		% of Total	20.0%	20.0%	12.5%	52.5%
Total		Count	11	18	11	40
		% within	27.5%	45.0%	27.5%	100.0%
		IMT_kategori				
		% within Fenotipe	100.0%	100.0%	100.0%	100.0%
		% of Total	27.5%	45.0%	27.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	2.492 ^a	2	.288
Likelihood Ratio	2.572	2	.276
N of Valid Cases	40		

a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.23.



Menarche_kategori * Fenotipe

Crosstab

		Fenotipe			Total
		A	C	D	
Menarche_kategori < 12 tahun	Count	2	1	0	3
	% within Menarche_kategori	66.7%	33.3%	0.0%	100.0%
	% within Fenotipe	18.2%	5.6%	0.0%	7.5%
	% of Total	5.0%	2.5%	0.0%	7.5%
> = 12 tahun	Count	9	17	11	37
	% within Menarche_kategori	24.3%	45.9%	29.7%	100.0%
	% within Fenotipe	81.8%	94.4%	100.0%	92.5%
	% of Total	22.5%	42.5%	27.5%	92.5%
Total	Count	11	18	11	40
	% within Menarche_kategori	27.5%	45.0%	27.5%	100.0%
	% within Fenotipe	100.0%	100.0%	100.0%	100.0%
	% of Total	27.5%	45.0%	27.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	2.799 ^a	2	.247
Likelihood Ratio	3.156	2	.206
N of Valid Cases	40		

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is ,83.



Pekerjaan_kategori * Fenotipe

Crosstab

			Fenotipe			Total
			A	C	D	
Pekerjaan_kategori	Tidak bekerja	Count	2	3	5	10
		% within Pekerjaan_kategori	20.0%	30.0%	50.0%	100.0%
		% within Fenotipe	18.2%	16.7%	45.5%	25.0%
		% of Total	5.0%	7.5%	12.5%	25.0%
	Bekerja	Count	9	15	6	30
		% within Pekerjaan_kategori	30.0%	50.0%	20.0%	100.0%
		% within Fenotipe	81.8%	83.3%	54.5%	75.0%
		% of Total	22.5%	37.5%	15.0%	75.0%
Total	Count	11	18	11	40	
	% within Pekerjaan_kategori	27.5%	45.0%	27.5%	100.0%	
	% within Fenotipe	100.0%	100.0%	100.0%	100.0%	
	% of Total	27.5%	45.0%	27.5%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	3.394 ^a	2	.183
Likelihood Ratio	3.177	2	.204
N of Valid Cases	40		

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is 2,75.



Pendidikan_kategori * Fenotipe

Crosstab

		Fenotipe			Total
		A	C	D	
Pendidikan_kategori <= 9 tahun	Count	1	5	2	8
	% within Pendidikan_kategori	12.5%	62.5%	25.0%	100.0%
	% within Fenotipe	9.1%	27.8%	18.2%	20.0%
	% of Total	2.5%	12.5%	5.0%	20.0%
> 9 tahun	Count	10	13	9	32
	% within Pendidikan_kategori	31.3%	40.6%	28.1%	100.0%
	% within Fenotipe	90.9%	72.2%	81.8%	80.0%
	% of Total	25.0%	32.5%	22.5%	80.0%
Total	Count	11	18	11	40
	% within Pendidikan_kategori	27.5%	45.0%	27.5%	100.0%
	% within Fenotipe	100.0%	100.0%	100.0%	100.0%
	% of Total	27.5%	45.0%	27.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	1.521 ^a	2	.467
Likelihood Ratio	1.629	2	.443
N of Valid Cases	40		

a. 3 cells (50,0%) have expected count less than 5. The minimum expected count is 2,20.



Crosstab

			Anxiety		Total
			RINGAN	SEDANG	
fenotipe_kategori	A	Count	6	5	11
		% within fenotipe_kategori	54.5%	45.5%	100.0%
		% within Anxiety	26.1%	29.4%	27.5%
		% of Total	15.0%	12.5%	27.5%
	C	Count	12	6	18
		% within fenotipe_kategori	66.7%	33.3%	100.0%
		% within Anxiety	52.2%	35.3%	45.0%
		% of Total	30.0%	15.0%	45.0%
	D	Count	5	6	11
		% within fenotipe_kategori	45.5%	54.5%	100.0%
		% within Anxiety	21.7%	35.3%	27.5%
		% of Total	12.5%	15.0%	27.5%
Total	Count	23	17	40	
	% within fenotipe_kategori	57.5%	42.5%	100.0%	
	% within Anxiety	100.0%	100.0%	100.0%	
	% of Total	57.5%	42.5%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)
Pearson Chi-Square	1.311 ^a	2	.519
Likelihood Ratio	1.317	2	.518
N of Valid Cases	40		

a. 2 cells (33,3%) have expected count less than 5. The minimum expected count is 4,68.



Crosstab

			Anxiety		Total
			RINGAN	SEDANG	
fenotipe_2kategori	A dan B	Count	6	5	11
		% within fenotipe_2kategori	54.5%	45.5%	100.0%
		% within Anxiety	26.1%	29.4%	27.5%
		% of Total	15.0%	12.5%	27.5%
	C dan D	Count	17	12	29
		% within fenotipe_2kategori	58.6%	41.4%	100.0%
		% within Anxiety	73.9%	70.6%	72.5%
		% of Total	42.5%	30.0%	72.5%
Total		Count	23	17	40
		% within fenotipe_2kategori	57.5%	42.5%	100.0%
		% within Anxiety	100.0%	100.0%	100.0%
		% of Total	57.5%	42.5%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2- sided)	Exact Sig. (2- sided)	Exact Sig. (1- sided)
Pearson Chi-Square	.054 ^a	1	.816	1.000	.546
Continuity Correction ^b	.000	1	1.000		
Likelihood Ratio	.054	1	.816		
Fisher's Exact Test					
N of Valid Cases	40				

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 4,68.

b. Computed only for a 2x2 table



Risk Estimate

	Value	95% Confidence Interval	
		Lower	Upper
Odds Ratio for fenotipe_2kategori (A dan B / C dan D)	.847	.209	3.428
For cohort Anxiety = RINGAN	.930	.500	1.730
For cohort Anxiety = SEDANG	1.098	.504	2.394
N of Valid Cases	40		

Uji normalitas

Tests of Normality

	Fenotipe	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
Kortisol	A	.177	11	.200*	.929	11	.402
	C	.174	18	.154	.948	18	.398
	D	.298	11	.007	.876	11	.092
Skor_anxiety	A	.196	11	.200*	.919	11	.311
	C	.150	18	.200*	.969	18	.773
	D	.241	11	.073	.887	11	.128

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Uji Independent sample t test

Group Statistics

ANxiety_kategori	N	Mean	Std. Deviation	Std. Error Mean
Ringan	23	6.7078	2.57680	.53730
Sedang	17	7.6964	3.36624	.81643



Independent Samples Test

	Levene's Test for Equality of Variances		t-test for Equality of Means							
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference		
								Lower	Upper	
Kortisol	Equal variances assumed	3.478	.070	-1.053	38	.299	-.98863	.93881	2.88915	.91189
	Equal variances not assumed			-1.012	28.916	.320	-.98863	.97737	2.98783	1.01057

Uji ANOVA

Descriptives

Kortisol

	N	Mean	Std. Deviation	Std. Error	95% Confidence Interval for Mean		Minimum	Maximum
					Lower Bound	Upper Bound		
A	11	8.0723	2.51635	.75871	6.3818	9.7628	4.27	11.42
C	18	7.0121	3.12405	.73634	5.4586	8.5657	2.69	13.16
D	11	6.3731	3.02296	.91146	4.3422	8.4039	2.38	13.14
Total	40	7.1279	2.93928	.46474	6.1879	8.0680	2.38	13.16



Test of Homogeneity of Variances

Statistic	df1	df2	Sig.
.690	2	37	.508

ANOVA

Kortisol

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	16.318	2	8.159	.942	.399
Within Groups	320.618	37	8.665		
Total	336.936	39			

Kruskal-Wallis Test

Ranks

	fenotipe_kategori	N	Mean Rank
Ansietas	A	11	15.41
	C	18	14.75
	Total	29	
Ketegangan	A	11	16.64
	C	18	14.00
	Total	29	
Ketakutan	A	11	14.95
	C	18	15.03
	Total	29	
Gangguan_tidur	A	11	15.09
	C	18	14.94
	Total	29	
Gangguan_kecerdasan	A	11	15.36
	C	18	14.78
	Total	29	
Gangguan_depresi	A	11	14.64
	C	18	15.22
	Total	29	
Somatik_otot	A	11	14.82
	C	18	15.11
	Total	29	
Sensorik	A	11	14.68
	C	18	15.19
	Total	29	
uler	A	11	13.27



	C	18	16.06
	Total	29	
Respiratori	A	11	14.23
	C	18	15.47
	Total	29	
Pencernaan	A	11	14.23
	C	18	15.47
	Total	29	
Urogenital	A	11	16.05
	C	18	14.36
	Total	29	
otonom	A	11	17.18
	C	18	13.67
	Total	29	
Wawancara	A	11	15.59
	C	18	14.64
	Total	29	

Test Statistics^{a,b}

	An sie ta s	Ket ega nga n	Ket ak uta n	Gang guan tidur	Gangguan_ kecerd asan	Gangg uan_de presi	Som atik_ otot	Somat ik_sen sorik	Kard ioas kuler	Re spir ator i	Pen cern aan	Uro ge nita l	ot o n o m	Wa wan car a
C hi - S q u ar e	.048	.827	.001	.003	.048	.066	.029	.128	.972	.227	.523	.620	3.245	.117
	1	1	1	1	1	1	1	1	1	1	1	1	1	1



A s y m p. S i g.	.8 27	.363	.97 7	.959	.826	.798	.865	.720	.324	.63 4	.470	.43 1	.0 7 2	.73 2
--	----------	------	----------	------	------	------	------	------	------	----------	------	----------	--------------	----------

a. Kruskal Wallis Test

b. Grouping Variable: fenotipe_kategori

